Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
| Autor: | Nuriye Ozdemir, Irem Bilgetekin, Esra Zeynelgil, Mustafa Altinbaş, Ismail Erturk, Selin Akturk Esen, Dogan Uncu, Musa Baris Aykan, Goksen Inanc Imamoglu, Yeşim Yıldız, Cengiz Karacin, Ahmet Ozet, Burak Civelek, Ismail Celik, Gokhan Ucar, Fatma Buğdaycı Başal, Nuri Karadurmus, Ozan Yazıcı, Bedia Dinc, Ibrahim Karadag, Omur Berna Oksuzoglu, Osman Sütcüoğlu, Yakup Ergun, Mutlu Dogan, Tulay Eren |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
safety tumors Cancer Research medicine.medical_specialty COVID-19 Vaccines medicine.drug_class medicine.medical_treatment Antineoplastic Agents immunogenicity Antibodies Viral chemotherapy Monoclonal antibody Systemic therapy 03 medical and health sciences Immunogenicity Vaccine 0302 clinical medicine Double-Blind Method Neoplasms vaccine Internal medicine medicine Humans cancer In patient Prospective Studies 030212 general & internal medicine Aged Aged 80 and over Chemotherapy SARS-CoV-2 business.industry Immunogenicity COVID-19 Cancer General Medicine Immunotherapy Odds ratio Middle Aged medicine.disease Vaccines Inactivated Oncology monoclonal antibody 030220 oncology & carcinogenesis Female immunotherapy business Research Article |
| Zdroj: | Future Oncology |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2021-0597 |
| Popis: | Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 μg/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as ‘immunogenicity.’ Results: The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio: 0.830; p = 0.043). Conclusion: More than half of cancer patients receiving active systemic therapy developed immunogenicity. Tweetable abstract Immunogenicity developed with CoronaVac in 25 (59.5%) of 42 patients who received at least one cytotoxic drug and in all patients (n = 5) who received monoclonal antibody or immunotherapy alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|